WellStreet Urgent Care, bioMérieux celebrate 200,000 patients served through BIOFIRE® SPOTFIRE® tests in urgent care clinics across Georgia, Ohio and South Ca…

WellStreet Urgent Care, an expert in developing and scaling urgent care networks with health system partners, and bioMérieux, ...
Nasdaq

bioMérieux: BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 Obtains FDA Emergency Use Authorization

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...
News Medical

FDA authorizes marketing of first SARS-CoV-2 diagnostic test using De Novo premarket review pathway

Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and ...
Pharmabiz

US FDA grants marketing authorization to BioFire’s Respiratory Panel 2.1 to detect SARS-CoV-2

The US Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification ...
Business Insider

Private GP clinic Sloane Street Surgery marks one year of same-day diagnostic testing, transforming infection care for London patients

Sloane Street Surgery’s BioFire testing provides same-day identification of infections, allowing faster, safer and more targeted treatment London, England, United Kingdom, November 25, 2025-- Sloane ...
Business Wire

BioFire Submits Special 510(k) Application to the FDA for the use of FilmArray ® Torch, the New High Throughput FilmArray ® System with FilmArray ® Respiratory Panel

MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, LLC, its molecular ...
Finanznachrichten

bioMérieux: BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization

bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has ...